Sign In
Buy ALRN
$2.11
+0 (+0%)
At Close: Apr 09, 2025
ALRN Stock: What Investors Should Know About Aileron Therapeutics
10:34am, Tuesday, 05'th Jan 2021
As with many biopharma names, there's volatility and risk in ALRN stock. This firm is seeking to reduce the effects of chemotherapy.
Aileron Therapeutics Reports Third Quarter 2020 Financial Results and Business Highlights
07:03pm, Thursday, 12'th Nov 2020
WATERTOWN, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN) today reported business highlights and financial results for the third quarter ended September 30, 2020.
Sens announcement for INVESTEC AUSTRALIA PROPERTY FUND – Release of Explanatory Memorandum and Independent Expert’s Report and Withdrawal of Statements - SENS
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Aileron Therapeutics
Aileron Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update
08:10pm, Wednesday, 05'th Aug 2020
* Company continues to develop ALRN-6924 as novel chemoprotective medicine to protect patients from chemotherapy-induced toxicities and side effects \-- Positive interim dose optimization data from p
3 “Strong Buy” Penny Stocks That Could Go Boom
11:42pm, Tuesday, 04'th Aug 2020
The stock market has been holding up remarkably well, but why? Against the backdrop of weak second quarter earnings results, investors are piling in on
3 “Strong Buy” Penny Stocks That Could Go Boom
07:31pm, Tuesday, 04'th Aug 2020
The stock market has been holding up remarkably well, but why? Against the backdrop of weak second quarter earnings results, investors are piling in on the hope that a COVID-19 vaccine is coming, ther
MyoKardia Heart Trial, And Other News: The Good, Bad And Ugly Of Biopharma (NASDAQ:MYOK)
03:41pm, Tuesday, 04'th Aug 2020
MyoKardia reports initiating trial for invasive septal reduction therapy. Aileron completes enrollment in chemotherapeutic agent trial.
Aileron Therapeutics to Present at Two Upcoming Investor Conferences in August
12:10pm, Monday, 03'rd Aug 2020
WATERTOWN, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN) today announced that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, will participate in two u
* Study is evaluating ALRN-6924 to protect against chemotherapy-induced bone marrow toxicities in patients with p53-mutated small cell lung cancer (SCLC) treated with topotecan * Previously repor
Hoth Therapeutics (NASDAQ:HOTH) and Aileron Therapeutics (NASDAQ:ALRN) Head-To-Head Comparison
01:36am, Monday, 03'rd Aug 2020
Hoth Therapeutics (NASDAQ:HOTH) and Aileron Therapeutics (NASDAQ:ALRN) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of t
Analysts Expect Aileron Therapeutics Inc (NASDAQ:ALRN) to Post -$0.16 Earnings Per Share
06:24am, Monday, 20'th Jul 2020
Wall Street brokerages expect that Aileron Therapeutics Inc (NASDAQ:ALRN) will announce earnings per share of ($0.16) for the current quarter, Zacks reports. Zero analysts have issued estimates for Ai
C4 Therapeutics Announces the Additions of William McKee as Chief Financial Officer and Jolie M. Siegel as Chief Legal Officer
12:00am, Wednesday, 15'th Jul 2020
C4 Therapeutics Announces the Additions of William McKee as Chief Financial Officer and Jolie M. Siegel as Chief Legal Officer
Analysts' Top Healthcare Picks: Bristol Myers (BMY), Viking Therapeutics (VKTX) - Markets
03:58pm, Thursday, 02'nd Jul 2020
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Bristol Myers
-- Novel approach leverages the ability of intracellular p53 protein to induce cell cycle arrest in healthy cells to prevent severe toxicities driven by chemotherapy’s.
